Inclusion Criteria:

- Symptomatic myeloma diagnosis according to criteria in attachment 3

- ASCT is performed or has been performed in the last five weeks (time limit two weeks
for patients randomised at 2nd transplantation) as a part of primary therapy

- Signed informed consent given prior to any study related activities have been
performed

Exclusion Criteria:

- Prior exposure to bortezomib

- Allogeneic transplantation scheduled as a part of the primary treatment

- Neuropathy > Grade 2 (neurological symptoms interfering with ADL)

- Non-secreting myeloma

- Other concurrent disease making bortezomib treatment unsuitable

- Positive pregnancy test (only applicable for women with childbearing potential)

- Has known or suspected hypersensitivity or intolerance to boron, mannitol, or
heparin, if an indwelling catheter is used

- Uncontrolled or severe cardiovascular disease including myocardial infarction within
6 months of enrolment, New York Heart Association (NYHA) Class III or IV heart
failure (Attachment 6, NYHA Classification of Cardiac Disease), uncontrolled angina,
clinically significant pericardial disease, or cardiac amyloidosis

- History of hypotension or has decreased blood pressure (sitting systolic blood
pressure [SBP] £100 mmHg and/or sitting diastolic blood pressure [DBP] £60 mmHg)

- Serious medical or psychiatric illness likely to interfere with participation in this
clinical study

- Have received an experimental drug or used an experimental medical device within 4
weeks prior to inclusion into the study